Effect of cytarabine and decitabine in combination in human leukemic cell lines

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4225-4232

  Qin, Taichun ^a   Youssef, Emile M ^a   Jelinek, Jaroslav ^a   Chen, Rong ^a   Yang, Allen S ^b   Garcia Manero, Guillermo ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTARABINE; GENOMIC DNA; LIPOCORTIN 5;

ALU SEQUENCE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; EPIGENETICS; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL;

ANNEXIN A5; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CYTARABINE; DNA METHYLATION; DNA, NEOPLASM; HL-60 CELLS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34547125965     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2762     Document Type: Article

References (31)

1. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-7.
2. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood 2001;97:2823-9.
3. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-44.
4. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77.
5. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7.
6. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006;66:5495-503.
7. Johnson SA. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2001;2:929-43.
8. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209-19.
9. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74.
10. Hubeek I, Peters GJ, Broekhuizen AJ, et al. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. Br J Haematol 2005;131:219-22.
11. Colombo T, Rossi C, D'Incalci M. Antagonism of 5-aza-2′- deoxycytidine antileukemic activity by concomitant treatment with cytarabine. Cancer Treat Rep 1986;70:1451-3.
12. Evans JS, Mengel GD. The reversal of cytosine arabinoside activity in vivo by deoxycytidine. Biochem Pharmacol 1964;13:989-94.
13. Graham FL, Whitmore GF. The effect of β-D- arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 1970;30:2627-35.
14. Gomyo Y, Sasaki J, Branch C, Roth JA, Mukhopadhyay T. 5-Aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 2004;23:6779-87.
15. Kong XB, Tong WP, Chou TC. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol Pharmacol 1991;39:250-7.
16. Richel DJ, Colly LP, Willemze R. The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia. Bone Marrow Transplant 1989;4 Suppl 3:64.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
19. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 2003;23:206-15.
20. Hwu HR, Roberts JW, Davidson EH, Britten RJ. Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proc Natl Acad Sci U S A 1986;83:3875-9.
21. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24:88-91.
22. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A 1997;94:4681-5.
23. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001;15:875-90.
24. Townsend AJ, Cheng YC. Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of chain elongation on a defined template. Mol Pharmacol 1987;32:330-9.
25. Moriai R, Tsuji N, Kobayashi D, et al. A proapoptotic caspase recruitment domain protein gene, TMS1, is hypermethylated in human breast and gastric cancers. Anticancer Res 2002;22:4163-8.
26. Liu WM, Stimson LA, Joel SP. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. Br J Cancer 2002;86:1472-8.
27. Nakamura M, Ishida E, Shimada K, Nakase H, Sakaki T, Konishi N. Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas. Oncology 2006;70:212-21.
28. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
29. Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M. Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4- hydroperoxycyclophosphamide with human tumor cells. Cancer Res 1990;50:4572-7.
30. La Rosee P, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004;103:208-15.
31. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.